These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33098615)

  • 1. The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
    Li Z; Murakoshi M; Ichikawa S; Koshida T; Adachi E; Suzuki C; Ueda S; Gohda T; Suzuki Y
    FEBS Open Bio; 2020 Dec; 10(12):2761-2770. PubMed ID: 33098615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
    Ishibashi Y; Matsui T; Yamagishi SI
    Diab Vasc Dis Res; 2016 Nov; 13(6):438-441. PubMed ID: 27407083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
    Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y
    Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice.
    Hanaguri J; Yokota H; Kushiyama A; Kushiyama S; Watanabe M; Yamagami S; Nagaoka T
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
    Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
    J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria.
    Shimohata H; Iwaki Y; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
    Int Urol Nephrol; 2022 Aug; 54(8):1907-1914. PubMed ID: 34843041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.
    Iwamoto M; Kubota T; Sakurai Y; Wada N; Shioda S; Yamauchi T; Kadowaki T; Kubota N
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00971. PubMed ID: 35707828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
    Locatelli M; Zoja C; Conti S; Cerullo D; Corna D; Rottoli D; Zanchi C; Tomasoni S; Remuzzi G; Benigni A
    J Pathol; 2022 Apr; 256(4):468-479. PubMed ID: 35000230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
    Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
    PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
    Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressive effects of the sodium‑glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice.
    Kato J; Shirakami Y; Ohnishi M; Mizutani T; Kubota M; Sakai H; Ibuka T; Tanaka T; Shimizu M
    Oncol Rep; 2019 Dec; 42(6):2797-2805. PubMed ID: 31638239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
    van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH
    Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
    Ikeda S; Takano Y; Schwab D; Portron A; Kasahara-Ito N; Saito T; Iida S
    Drug Res (Stuttg); 2019 Jun; 69(6):314-322. PubMed ID: 30103216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.